TELEFLEX (TFX) Company Report

Teleflex entered into definitive agreements to sell its Acute Care and Interventional Urology businesses to Intersurgical Ltd and its OEM business to Montagu and Kohlberg for a combined $2.03 billion in cash, subject to closing adjustments.
Under the agreements, the company expects to receive approximately $1.5 billion for the OEM business and $530 million for the Acute Care and Interventional Urology businesses, yielding net proceeds of about $1.8 billion after tax.
The transactions are expected to close in the second half of 2026, subject to customary regulatory approvals and closing conditions.
Teleflex’s Board has authorized a new $1 billion share repurchase program, to be primarily funded with proceeds from these sales.

15 hours ago

8-K

Teleflex to sell Medical OEM unit to Montagu and Kohlberg

TFX

M&A

Management Change

Teleflex agreed to sell its Medical OEM unit to Montagu and Kohlberg for $1.5 billion, with closing expected in H2 2026
Teleflex Medical OEM is a leading contract developer and manufacturer with seven facilities across the U.S., Mexico, and Ireland
Upon closing, Greg Stotts will become Chief Executive Officer of the standalone company
Montagu and Kohlberg will apply their carve-out expertise and healthcare investment track record to drive the unit’s growth

22 hours ago

Press Release

Teleflex announces sale of Acute Care, Interventional Urology, and OEM businesses

TFX

M&A

Share Buyback

Teleflex agreed to sell its Acute Care and Interventional Urology units to Intersurgical Ltd and its OEM business to Montagu and Kohlberg for $2.03 billion in cash.
The OEM business sale is valued at $1.5 billion and the Acute Care and Interventional Urology units at $530 million, with expected closing in 2H 2026.
Net proceeds are estimated at $1.8 billion after tax, which Teleflex intends to use for debt reduction and shareholder returns.
The company also authorized up to $1 billion in share repurchases, primarily funded by sale proceeds.

23 hours ago

Press Release

Teleflex outlines RemainCo focus and Nuco sale strategy at Jefferies London Healthcare Conference

TFX

M&A

New Projects/Investments

Teleflex is pursuing the separation of Nuco via spin or sale, prioritizing a sale due to strong inbound interest, with potential transaction execution expected before mid-2026.
The proposed RemainCo will simplify operations from 7 to 3 business units and from 19 to 7 manufacturing sites, targeting mid-single digit growth, ~5% R&D spend, and improved margins; BIOTRONIK VI contributed ~7% growth in its first year.
Integration of BIOTRONIK’s interventional portfolio (50% Europe, 25% US, 25% Asia) provides geographic and product synergies in complex PCI, peripheral products, and optional scaffold technology Freesolv (Biomag 2 readout in late 2027).
The global balloon pump business saw accelerated share gains but slowed earlier than expected in Q3; full-year 2025 revenue forecast revised from $110M to $80M, with long-term outlook unchanged.
Pricing headwinds eased: tariff impact reduced from $55M to $26M in 2025 via increased USMCA compliance (from 50% to 70%); China volume-based procurement now covers almost the entire portfolio, with growth bottom in Q1 improving through Q3 and recovery expected by year-end.

Nov 18, 2025, 10:00 AM

Transcript

Teleflex prioritizes sale of NewCo over spin at Jefferies Conference

TFX

M&A

Teleflex is prioritizing a sale of NewCo rather than a spin and expects the transaction could close before mid-2026, with the spin remaining as a fallback to maximize shareholder value.
RemainCo will be streamlined to three global business units and seven manufacturing sites, targeting mid-single digit growth (approximately 5% in 9M25 ex-VBP), bolstered by the BIOTRONIK VI acquisition which grew ~7% in its first full-year under Teleflex.
The BIOTRONIK VI integration enhances Teleflex’s complex PCI offerings, expands geographic reach in Europe and Asia, and adds a pipeline scaffold (Freesolve) undergoing BIOMAG-II and BIOMAG-III studies.
RemainCo’s gross margins are expected to exceed Teleflex’s current levels, with operating margins on par, despite initial stranded costs which will be offset by transitional service agreements post-sale.
Teleflex mitigated a $55 million tariff impact to ~$26 million through China tariff reductions and USMCA content increases to 70%, and has largely completed China volume-based procurement across RemainCo’s portfolio.

Nov 18, 2025, 10:00 AM

Transcript

Teleflex outlines growth strategy for acquired vascular intervention business

TFX

M&A

Teleflex acquired BIOTRONIK’s vascular intervention business on June 30, 2025, combining it with its interventional unit to offer a comprehensive coronary and peripheral portfolio and capture synergies in engineering, manufacturing, and commercial execution.
The combined portfolio includes the Orsiro Mission drug-eluting stent, Pantera Lux and Paseo 18 Lux drug-coated balloons, and the FreeSolve resorbable magnesium scaffold, with VI revenues split roughly 50% EMEA, 25% North America, and 25% Asia-Pacific; US DCB launches are planned in coming years.
The FreeSolve RMS pipeline features Biomag 1 three-year data showing 3.5% target lesion failure, Biomag 2 CE trial >50% enrolled (1-year results by end 2027), Biomag LL enrolling in Europe/Asia, and Biomag 3 US pivotal in finalization; below-the-knee RMS holds FDA breakthrough designation.
The North American vascular intervention sales team is being expanded by approximately 50%, leveraging Teleflex’s existing cath-lab relationships to cross-sell and increase market access globally.
The VI business grew ~6% in the first quarter of ownership and is expected to sustain 6%+ annual growth, with operating-margin expansion as synergies and efficiencies are realized.

Nov 14, 2025, 1:00 PM

Transcript

Teleflex provides Vascular Intervention business update

TFX

Teleflex’s Vascular Intervention business addresses a $6.4 bn Coronary VI market (mid single-digit % growth) and a $3.6 bn Peripheral VI market (high single-digit % growth).
The strategy rests on four growth drivers: underlying organic market growth, expanded market and account access, a differentiated product portfolio, and strong customer engagement and education.
The R&D pipeline is expected to add $1.0 bn in coronary VI and $3.1 bn in peripheral VI market value by 2033.
In 2024, Vascular Intervention sales were split 53% EMEA, 21% Americas, 26% APAC, with 73% from Coronary and 26% from Peripheral products (VRT <1%).

Nov 14, 2025, 1:00 PM

Presentation

Teleflex outlines Vascular Intervention acquisition and growth strategy

TFX

M&A

Revenue Acceleration/Inflection

New Projects/Investments

Teleflex acquired BIOTRONIK’s Vascular Intervention business on June 30, 2025, creating a combined portfolio spanning coronary and peripheral devices, including drug-eluting stents, drug-coated balloons, and resorbable magnesium scaffolds (RMS).
By 2050, global coronary heart disease incidence is projected to grow 116% to 67.3 million, prevalence 80% to 510 million, and peripheral vascular disease incidence 220% to 360 million, driving demand for advanced interventional therapies.
Integration synergies include expanding the North American sales force by ~50% and leveraging Teleflex’s complex PCI relationships, contributing to a 7% revenue increase last quarter driven by covered stents and DCBs.
R&D pipeline highlights BIOMAG-I data with a 3.5% target lesion failure rate at three years for Freesolve RMS, ongoing BIOMAG-II and CE/US trials, and new DES, DCB, and peripheral devices such as Coya ultra-high-pressure and iliac covered stents.

Nov 14, 2025, 1:00 PM

Transcript

Teleflex hosts investor meeting on vascular intervention integration

TFX

M&A

New Projects/Investments

Revenue Acceleration/Inflection

Teleflex acquired BIOTRONIK’s vascular intervention business on June 30, 2025, merging it with legacy Interventional to support both coronary and peripheral vascular domains under one platform.
The combined portfolio spans drug-eluting stents (Orsiro Mission), drug-coated balloons (Pantera Lux, Paseo 18 Lux), covered stents (PK Papyrus), and resorbable magnesium scaffolds (FreeSolve RMS), targeting leave-nothing-behind and complex PCI strategies.
FreeSolve RMS’s Biomag platform shows a 3.5% target lesion failure rate at three years with no new events between 18–36 months; trials are advancing—Biomag 2 >50% enrolled (one-year data by end-2027), Biomag LL and US pivotal Biomag 3 in progress.
The sales force will expand by ~50% in North America, convert key distributors to direct sales, and leverage synergies to achieve 6%+ annual growth and margin expansion over the next 12–18 months.

Nov 14, 2025, 1:00 PM

Transcript

Teleflex reports Q3 2025 results

TFX

Earnings

Guidance Update

M&A

Revenue of $913 million in Q3, up 19.4% YoY on a GAAP basis; adjusted revenue $892.9 million, up 16.8% reported / 15.3% constant currency.
Adjusted EPS of $3.67, + 5.2% YoY; adjusted gross margin 57.3% (-350 bps) and adjusted operating margin 23.3% (-400 bps), pressured by tariffs, FX, and mix.
Advancing separation into Remainco and Newco, with sale of Newco as priority; proceeds earmarked for debt reduction and shareholder returns.
2025 guidance lowered: adjusted constant currency revenue growth of 6.9–7.4% (implying $3.305–3.320 billion) and adjusted EPS narrowed to $14.00–14.20.
Acquired vascular intervention business delivered modestly above $99 million expectation and 6.9% YoY growth; integration on track, with Biomag 2 trial at 1,000 patients enrolled.

Nov 6, 2025, 1:00 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for TELEFLEX.

Q3 2025

Nov 6, 2025

→

Q2 2025

Jul 31, 2025

→

Q1 2025

May 1, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Liam Kelly say about margins?What are TELEFLEX's strategic priorities?How is TELEFLEX positioned vs competitors?How did TELEFLEX do last quarter?

TELEFLEX (TFX)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Liam Kelly

Daniel Logue

James Winters

Jay White

John Deren

Board Members

Andrew Krakauer

Candace Duncan

Gretchen Haggerty

Jaewon Ryu

John Heinmiller

Neena Patil

Stephen Klasko

Stuart Randle

Analyst Coverage

Anthony Petrone

Jayson Bedford

Shagun Singh Chadha

Craig Bijou

Matthew O'Brien

Michael Matson

Michael Polark

Patrick Wood

Richard Newitter

Larry Biegelsen

David Turkaly

Kristen Stewart

Matthew Taylor

Matt Taylor

Michael Sarcone

Mike Matson

Mike Polark

Ravi Misra

Vikramjeet Chopra

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent